Statement of Changes in Beneficial Ownership (4)

Date : 11/19/2019 @ 9:06PM
Source : Edgar (US Regulatory)
Stock : Eidos Therapeutics Inc (EIDX)
Quote : 42.02  -6.32 (-13.07%) @ 10:20PM
Eidos Therapeutics share price Chart

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Fox Jonathan C
2. Issuer Name and Ticker or Trading Symbol

Eidos Therapeutics, Inc. [ EIDX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000
3. Date of Earliest Transaction (MM/DD/YYYY)

11/15/2019
(Street)

SAN FRANCISCO, CA 94104
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/15/2019  S(1)  2000 D$44.8786 (2)484527 I See footnote (5)
Common Stock 11/15/2019  S(1)  2100 D$45.5082 (3)482427 I See footnote (5)
Common Stock 11/15/2019  S(1)  900 D$46.45 (4)481527 I See footnote (5)
Common Stock 11/18/2019  S(1)  10000 D$50.2574 (6)471527 I See footnote (5)
Common Stock         2850 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(2) Represents the weighted average sale price of the shares ranging from $44.23 to $45.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
(3) Represents the weighted average sale price of the shares ranging from $45.24 to $46.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
(4) Represents the weighted average sale price of the shares ranging from $46.39 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
(5) The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014.
(6) Represents the weighted average sale price of the shares ranging from $50.00 to $50.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Remarks:
President and Chief Medical Officer

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Fox Jonathan C
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO, CA 94104


See Remarks

Signatures
/s/ Franco Valle, Attorney-in-fact11/19/2019
**Signature of Reporting PersonDate

Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart

1 Year : From Mar 2019 to Mar 2020

Click Here for more Eidos Therapeutics Charts.

Eidos Therapeutics (NASDAQ:EIDX)
Intraday Stock Chart

Today : Saturday 28 March 2020

Click Here for more Eidos Therapeutics Charts.

Latest EIDX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200328 09:38:20